Astero Erado Inc Profile last edited on: 7/19/2022
CAGE: 8HE35
UEI: Z3JWEMNYNRT9
Business Identifier: Advanced therapeutics through antibody-engineering 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
8405 Spring Creek
College Station, TX 77845
College Station, TX 77845
| (214) 219-4198 |
| admin@asteroerado.com |
| www.asteroerado.com |
Location: Single
Congr. District: 10
County: Brazos
Congr. District: 10
County: Brazos
Public Profile
Currently resident in Houston (JLABS @ TMC) , Astero Erado Inc is structured around first in class technology for the removal of pathogenic auto antibodies through selective antigen depletion. Principals of the fiirm indicate that they are developing the Seldeg approach to remove these auto antibodies. - ith the firm's product stage indicated as Preclinical (GLP Tox-IND)
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2024 | 2 | NIH | $598,849 | |
| Project Title: Novel treatments for Autoimmune Disease | ||||
| 2023 | 1 | NIH | $275,213 | |
| Project Title: Novel approaches for the treatment of autoimmune disease | ||||
| 2023 | 2 | NIH | $2,287,383 | |
| Project Title: Depleting autoantibodies for the treatment of autoimmunity | ||||
| 2021 | 1 | NIH | $250,915 | |
| Project Title: Targeting autoreactive antibodies for the therapy of MOG antibody-associated disease | ||||
| 2021 | 1 | NIH | $246,229 | |
| Project Title: Autoantibody depletion for the therapy of autoimmune disease | ||||
Key People / Management
Raimund Ober -- CEO
Sushrut Arora -- Principle Scientist
Sunil Kannanganat Sidharthan -- Principal Scientist
Sushrut Arora -- Principle Scientist
Sunil Kannanganat Sidharthan -- Principal Scientist
Company News
There are no news available.
